Who is eligible for clinical trial NCT07528157?

Participants must meet the protocol's inclusion criteria for Major Depressive Disorder. The stated age range is 18 Years to 65 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07528157 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-04-07

Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression (NCT07528157)

Early TMS-EEG Potentials as Biomarkers for Personalized Neuromodulation in Treatment-Resistant Depression (R61 Phase)

🟡 Not Yet Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol Sponsor: Stanford University

🩺 Plain-English Summary (8th-Grade Level)

This study tests whether a brain stimulation treatment for depression called intermittent theta burst stimulation (iTBS) can be improved by tailoring it to each individual. A type of brain signal measured with electroencephalography (EEG) after a single pulse of brain stimulation, called an early local TMS-evoked potential (EL-TEP), is used to identify which stimulation settings work best for each participant. The investigators will compare individualized (personalized) iTBS settings to standard (non-personalized) settings and to inactive (sham) stimulation. Participants are adults with treatment-resistant depression.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (8 items).

Location: Stanford University — Stanford, California

Age range: 18 Years to 65 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Aged 18-65 years
Clinical diagnosis of Major Depressive Disorder (MDD), confirmed by structured clinical interview
Current moderate-to-severe depressive episode (MADRS score ≥ 20)
Moderate-to-severe treatment resistance, assessed using the Maudsley Staging Method
Able to comprehend English sufficiently to complete study procedures and assessments
Able to maintain stable antidepressant regimen or remain medication-free for at least 4 weeks prior to and during the study

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Primary psychiatric diagnosis other than MDD
Contraindications to MRI (e.g., implanted metal)
Conditions or medications that may increase risk associated with TMS
Prior exposure to repetitive TMS (rTMS)
Non-response to electroconvulsive therapy (ECT)
History of psychosurgery for depression
High suicidal risk as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Stanford University — Stanford, California

📞 Contact the Study Coordinator

Phone: (408) 831-2366

Email: kellerlab@stanford.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Major Depressive Disorder

Multi-site Feasibility of an Integrated Treatment for the Biology and Experience of Depression: The MULTIBED Study — San Francisco, California
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression — Belmont, Massachusetts
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents — Birmingham, Alabama
Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial — Vancouver, British Columbia
Fisher Wallace Neurostimulation & Depression Study — New York, New York
RESISTance Exercise for Depression Trial — Ames, Iowa

Explore by condition: All Major Depressive Disorder clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗